Neuroradiological manifestations of neuroinflammatory diseases; A concept for rare cases and neuro-COVID-19

Abstract

Uncommon neurological diseases make for roughly half of all rare diseases. As one of the key players in the diagnostic process, neurologists require guidelines on the types of screening tests that can be done. In this sense, biomarker research has been very active. By minimizing the chance of misdiagnosis and improper therapy, diagnostic biomarkers may help reduce the risk of disease progression. Also, Neurological complications and associated radiological findings have been reported in an increasing number of patients with COVID-19 infection. Despite improved methods, diagnosing CNS inflammatory diseases is still difficult and time-consuming. Although MRI is essential in this procedure, it might be confusing in some circumstances due to overlapping radiological results. Considering the above facts, the necessity for specialized biomarkers seems to be paramount. Serological markers appear to merit special consideration. Peripheral blood samples, unlike CSF, are easily obtained in routine ambulatory care for many periods, allowing noninvasive monitoring of therapy response. A complete combination of clinical examination, radiographic assessment, laboratory tests, and often a multidisciplinary approach is required to make an accurate diagnosis.